Table 3.
Clinicopathologic Variables and the Expression Status of Nrf2, NQO1, MRP1, cmyc, and P53
| Variables | Total | Nrf2 | P | NQO1 | P | MRP1 | P | cmyc | P | P53 | P | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||||||||||
| Low | High | Low | High | Low | High | Low | High | Low | High | |||||||
| Duke’s staging | 0.005 | 0.009 | 0.013 | 0.113 | 0.001 | |||||||||||
| A | 20 | 14 | 6 | 14 | 6 | 15 | 5 | 11 | 9 | 13 | 7 | |||||
| B | 26 | 11 | 15 | 12 | 14 | 10 | 16 | 7 | 19 | 7 | 19 | |||||
| C | 27 | 6 | 21 | 7 | 20 | 10 | 17 | 12 | 15 | 4 | 23 | |||||
| D | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | |||||
| Age | 0.244 | 0.188 | 0.835 | 0.510 | 0.786 | |||||||||||
| <60 | 27 | 10 | 17 | 9 | 18 | 12 | 15 | 12 | 15 | 8 | 19 | |||||
| ≥60 | 49 | 21 | 28 | 24 | 25 | 23 | 26 | 18 | 31 | 16 | 33 | |||||
| Gender | 0.431 | 0.272 | 0.264 | 0.4 | 0.755 | |||||||||||
| Male | 40 | 18 | 22 | 15 | 25 | 16 | 24 | 14 | 26 | 12 | 28 | |||||
| Female | 36 | 13 | 23 | 18 | 18 | 19 | 17 | 16 | 20 | 12 | 24 | |||||